FindTrial
Sign In

Observation on the therapeutic effect of Yanggan Guben Formula on improving nutritional metabolism in patients with spleen kidney yang deficiency type liver cirrhosis ascites

Observation on the therapeutic effect of Yanggan Guben Formula on improving nutritional metabolism in patients with spleen kidney yang deficiency type liver cirrhosis ascites

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001375
Enrollment
Unknown
Registered
2025-07-11
Start date
2024-12-25
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Western medicine routine+Ganfu Pai+traditional Chinese medicine treatment group:Routine Western medicine treatment includes bed rest sodium restriction hepatoprotective drugs diuretics (such as spiron
Western Medicine Routine+Ganfu Pai Group:On the first day of admission according to the patients specific condition routine Western medicine treatment was given including bed rest sodium restriction h
Western medicine routine+traditional Chinese medicine treatment group:Conventional Western medicine treatments such as bed rest sodium restriction hepatoprotective drugs diuretics (such as spironolact

Sponsors

Ru Qingjing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosis of liver cirrhosis ascites with malnutrition in accordance with spleen kidney yang deficiency type (2) The patient is between the ages of 18 and 80 with no gender restrictions (3) Chlid Pugh classification B level or above (including B level (4) B-ultrasound examination classified ascites as grade 1 grade 2 or grade 3 (5) Voluntarily participate understand and sign the informed consent form

Exclusion criteria

Exclusion criteria: (1) Age under 18 years old or over 80 years old (2) Special populations such as pregnant women or those preparing to conceive those with mental illnesses (3) Patients with other serious primary diseases such as heart failure respiratory failure gastrointestinal infections ulcer disease and renal dysfunction are included in the combination (4) Patients with cardiogenic renal and tuberculous ascites (5) Allergic individuals to relevant research drugs (6) Those who are unwilling to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
Serum transferrin;extracellular moisture;SMI;total protein;albumin;Triceps skin fold;hand grips;Intracellular moisture;Basal Metabolic Rate;PA;BMI;Arm circumference;—

Secondary

MeasureTime frame
AST;ALT;TBIL;PT;PTA;—

Countries

China

Contacts

Public ContactRu Qingjing

The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

cshru@163.com13605810269

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026